Viking Therapeutics
VKTX
28.54
+0.16
+0.56%
Viking Therapeutics
US · VKTX
#2352 by market cap
Listed 2015
28.54
+0.16
+0.56%
Live - 5344 symbols - heartbeat 255s ago
· 2026-10-08 07:00
Pre-market
28.50
-0.14%
After-hours
28.62
+0.29%
Overnight
28.41
-0.46%
- Market cap
- 3.59B
- P/E (TTM)i
- -6.11
- P/Bi
- 8.78
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 16%
Reader sentiment
Are you bullish or bearish on VKTX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 16 analysts
Buy
Avg price target
90.47 +217.0%
Price target rangecurrent 28.54
Low38.00
Avg90.47
High125.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | CCORF | -- | BUY | 114.00 |
| 2026-09-23 | Maxim Group | -- | BUY | 70.00 |
| 2026-09-23 | Truist Financial | -- | BUY | 87.00 |
| 2026-09-23 | Jefferies | -- | BUY | 101.00 |
| 2026-09-23 | B. Riley Securities | -- | BUY | 85.00 |
| 2026-09-23 | Lake Street | -- | BUY | 89.00 |
| 2026-09-22 | William Blair | -- | BUY | -- |
| 2026-09-22 | Maxim Group | -- | BUY | 70.00 |
| 2026-09-22 | BTIG | -- | BUY | 125.00 |
| 2026-09-22 | Truist Financial | -- | BUY | 83.00 |
| 2026-09-22 | Morgan Stanley | -- | BUY | 95.00 |
| 2026-09-22 | Stifel | -- | BUY | 95.00 |
| 2026-09-22 | Goldman Sachs | -- | HOLD | 38.00 |
| 2026-09-22 | H.C. Wainwright | -- | BUY | 102.00 |
| 2026-09-22 | Oppenheimer | -- | BUY | 120.00 |
| 2026-09-09 | B. Riley Securities | -- | BUY | 85.00 |
| 2026-08-14 | Cantor Fitzgerald | -- | BUY | 100.00 |
| 2026-08-11 | J.P. Morgan | -- | BUY | 65.00 |
| 2026-08-03 | Oppenheimer | -- | BUY | 100.00 |
| 2026-07-31 | Maxim Group | -- | BUY | 70.00 |
| 2026-07-30 | CCORF | -- | BUY | 114.00 |
| 2026-07-30 | William Blair | -- | BUY | -- |
| 2026-07-30 | Piper Sandler | -- | BUY | 71.00 |
| 2026-07-30 | Maxim Group | -- | BUY | 70.00 |
| 2026-07-30 | Truist Financial | -- | BUY | 83.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-29 | After close | ±9.38% | -0.96% (in line) |
| 2026/Q1 | 2026-04-29 | After close | ±7.30% | -0.48% (in line) |
| 2025/Q4 | 2026-02-11 | After close | ±10.92% | +6.80% (in line) |
| 2025/Q3 | 2025-10-22 | After close | ±7.93% | +7.96% (beat) |
| 2025/Q2 | 2025-07-23 | After close | ±11.88% | +0.30% (in line) |
| 2025/Q1 | 2025-04-23 | After close | ±10.16% | -0.50% (in line) |
| 2024/Q4 | 2025-02-05 | After close | ±11.71% | -6.09% (in line) |
| 2024/Q3 | 2024-10-23 | After close | ±9.93% | +21.25% (beat) |
| 2024/Q2 | 2024-07-24 | After close | ±15.95% | +28.31% (beat) |
| 2024/Q1 | 2024-04-24 | After close | ±9.78% | +5.82% (in line) |
| 2023/Q4 | 2024-02-07 | After close | ±20.17% | +18.01% (in line) |
| 2023/Q3 | 2023-10-25 | After close | ±8.53% | -9.42% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.